Medication
Accel-Ondansetron ODT
DIN 02535319 · Accel Pharma Inc Likely a generic
What it is
- Active ingredients
- Ondansetron — 4 mg
- Form and route
- Tablet (Orally-Disintegrating) · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2023-12-19
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- PMS-Ondansetron
- Sandoz Ondansetron
- Apo-Ondansetron
- Teva-Ondansetron
- Mylan-Ondansetron
- Mint-Ondansetron
- Jamp-Ondansetron
- Mar-Ondansetron
- Ondissolve Odf
- Nat-Ondansetron
- Ondansetron
- Accel-Ondansetron
- Ondansetron ODT
- Mint-Ondansetron ODT
- Auro-Ondansetron ODT
- Mar-Ondansetron ODT
- Ondansetron ODT
- PMS-Ondansetron ODT
- Ondansetron ODT
- Jamp Ondansetron Odf
- Ondansetron
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Limited Use benefit Part XII
Ontario lists this product as a Limited Use benefit — Part XII of the Formulary/CDI. ODB pays for it only in the specific circumstances Ontario sets out against it, and the prescription has to carry a Limited Use code from the prescriber.
The criteria are set by Ontario and are not reproduced here — they are a matter for the prescriber.
- What ODB pays per unit
- $2.5450
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 4mg and will substitute one for another at a pharmacy counter in Ontario.
- Auro-Ondansetron ODT 02511282Auro Pharma Inc
- Jamp Ondansetron Odf 02541351Jamp Pharma Corporation
- Mar-Ondansetron ODT 02514966Marcan Pharmaceuticals Inc
- Mint-Ondansetron ODT 02487330Mint Pharmaceuticals Inc
- Ondansetron ODT 02481723Sandoz Canada Incorporated
- Ondansetron ODT 02519232Jamp Pharma Corporation
- Ondansetron ODT 02524279Sanis Health Inc
- Ondissolve Odf 02389983Takeda Canada Inc
- PMS-Ondansetron ODT 02519445Pharmascience Inc
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A04AA01
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A04AA01, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
Health Canada says: Return the affected products to your local pharmacy for a replacement, and for proper disposal. If you are unsure whether your product is affected, check with your pharmacy.Consult a health care professional if you have used the affected product and you have health concerns.Report any health product-related side effects or complaints to Health Canada.Contact the companies if you have questions about their recall:Accel Pharma Inc., by contacting Betty Cory at Accel Quality Assurance by calling 416-271-4775, or by email at bcory@regxia.com
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Accel-Ondansetron ODT → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.